Home Tags DAR

Tag: DAR

The Highs, Lows, and Resurgence of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) offer a way to deliver a cytotoxic or an immuno-stimulatory payload directly to tumors to maximize the anti-tumor efficacy of the payload with reduced systemic toxicities. The development of ADCs has occurred over several decades. ADCs have been through several highs and lows where there was substantial excitement for the promise ADCs hold only to be followed by disinterest when there were disappointing results in the clinic. This resulted in several companies abandoning their internal ADC development efforts. Twelve ADCs globally have been approved to treat hematologic or solid tumors. The renewed interest in ADCs, is due, in part, to the recent clinical success of ADCs, the development of improved ADC technologies, and the identification of new ADC targets.

National Institutes of Health Awards Development Grant to Applied BioMath for...

The U.S. National Institute of Health has awarded a development grant to Applied BioMath for a software platform called Antibody-drug Conjugate (ADC) Workbench.  The...

Abzena Signs Major ThioBridge™ Agreement with US Biotech Partner

Earlier today, Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announced that it had signed...

Novel Anti-CD22 Antibody-Drug Conjugate Shows Positive Pre-clinical Activity

The 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2015 in Philadelphia, PA, included a poster presentation...

Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma

Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...

X